Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: Final survival analysis of the ADEBAR study
W. Janni, N. Harbeck, B. Rack, D. Augustin, J. Jueckstock, A. Wischnik, K. Annecke, C. Scholz, J. Huober, T. Zwingers, T. W.P. Friedl, M. Kiechle
Research output: Contribution to journal › Article › peer-review
10Scopus
citations
Fingerprint
Dive into the research topics of 'Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: Final survival analysis of the ADEBAR study'. Together they form a unique fingerprint.